Colgate-Palmolive Co. (CL) shares are down 0.7% in premarket trades despite the toothpaste and toothbrush giant reporting better-than-expected fourth-quarter profit and hitting a full-year revenue ...
The Cambridge, Mass., biotechnology company on Thursday said it received a notice of allowance from the U.S. Patent and Trademark Office regarding the drug candidate, ED-003, which is intended to ...
A new study finds that only 20% of Gen Z is saving for retirement. Here, finance experts explain potential causes of this ...
The positive performance of the Indian stock was driven by strong profitability growth, rapid traction of digital financial ...
ROSELAND, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE ... with major indices like the S&P 500 and Dow Jones Industrial Average reaching record highs.
2024 was a landmark year for Dow Schofield Watts ... Read why 2024 was a significant milestone for DSW, here: https://lnkd.in/eQ8wMNPp ...
Wall Street is coming off a losing session after the Federal Reserve paused its interest rate-cutting campaign, leaving its ...
ECD Auto Design, the renowned leader in bespoke luxury vehicles, proudly announces the completion of its 600th SUV, a ...
Strategic Catalysts and Market Potential Drive Buy Rating for Milestone Pharmaceuticals’ CARDAMYST
Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) and keeping the price target at $25.00. Patrick Trucchio has given his ...
“2025 is set to be a transformative year for Milestone as we prepare for potential FDA approval of CARDAMYST and the opportunity to empower patients suffering with PSVT to self-manage episodes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback